Review
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 547-567
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.547
Table 3 Summary of studies over decades reporting on surveillance in inflammatory bowel disease
Ref.
Number of patients and cohort
Results
Conclusions benefit-yes/no
Rosenstock et al[136], 1985, Retrospective Review248 chronic UC patientsIn this cohort of patients: Overall incidence of HGD was 6%; HGD or carcinoma found in 24 procedures in 16 patients, mean disease duration of 16 yr, 15 patients had HGD; DALM most consistent indicator of carcinoma. > 95% of cancers 6 recognized at colonoscopyThe presence/absence of dysplasia a reliable histological marker that correlates with the presence/absence of cancer in UC. DALM with HGD had the strongest indication for surgery. Benefit- yes
Lashner et al[137], 1990, Prospective surveillance programme99 patients with pancolitisIn this cohort of patients: Both groups comparable in terms of age at onset, disease duration and gender; Total 8 fewer deaths in the surveillance group (P < 0.05); Colectomy was less common and was performed 4 yr later in the surveillance group (P < 0.05)Screening in UC associated with improved survival and delayed colectomy. Findings did not show improvement in cancer-related survival. Benefit-equivocal
Löfberg et al[138], 1990, 15-yr Prospective surveillance programme72 UC, 12 patients developed definite dysplasiaIn this cohort of patients: LGD detected in 7 patients; HGD in 4 and 1 Dukes' Stage-A cancer at operation; The cumulative risk of developing at least LGD was 14% after 25 yr of disease; Abnormal, aneuploid DNA content detected in biopsies of 12/59 patients (20.3%) this correlated significantly with LGD and HGDLong-term use of surveillance in UC is reliable in detecting dysplasia and identify patients for prophylactic surgery. Benefit-yes; Earlier detection of neoplasia
Nugent et al[139], 1991, 13-yr Prospective surveillance programme213 UC patientsIn this cohort of patients: A total of 15 patients underwent colectomy; A total of 7 patients had unsuspected carcinoma at various stages; Dysplasia detected among 11 patients; No difference in the prevalence of dysplasia between left-sided v/s extensive disease; No carcinoma detected among 175 patients without dysplasia on initial biopsiesSurveillance programme effective aid in reducing the risk of carcinoma in UC. Short term risk of CRC low if biopsy negative. Colectomy deferred in this group. Benefit-yes
Lynch et al[140], 1993, Prospective surveillance(between 1978 and 1990)160 UC patientsIn this cohort of patients: A total of 739 colonoscopies carried out (4.6 colonoscopies/per patient); A 709 patient-years follow-up was carried out; In 1 patient Dukes's A cancer was detected; IBD-CRC caused the death of 1 patient; Overall, 9 IBD-CRC cases were diagnosed during the study period but only 1 case was detected by way of the surveillance programmeResults of this large study with long follow-up cast doubts on the effectiveness of the surveillance programmes in detecting CRC in patients with UC. Benefit-no
Jonsson et al[141], 1994, Prospective, longitudinal study between 1977 and 1991131 patients with UCIn this cohort of patients: A total of 632 colonoscopies performed, dysplasia was diagnosed in 24 (4 HGD), other than those with cancer; CRC diagnosed in 4 patients, of whom 2 included in the programme with a diagnosis of cancer; CRC and dysplasia are seen mainly in the left colon and in pancolitis patientsThe surveillance programme was resource consuming and the cost-benefit must be questioned. Benefit-no. No cost-benefit as per authors
Karlén et al[142], 1998, Prospective case-control study4664 patients with UC, 142 patients with definite UCIn this cohort of patients: In 2 out of 40 patients with UC and 18/102 controls had at least one-surveillance colonoscopy (RR 0.29, 95% CI: 0.06-1.31); Out of 12 controls, only one patient with UC had two or more surveillance colonoscopies (RR 0.22, 95%CI: 0.03-1.74), indicating a protective dose-response relationSurveillance may be associated with decreased risk of death from CRC in patients with long-standing UC. Benefit-yes. May improve survival
Friedman et al[143], 2001, Prospective Longitudinal study259 patients with chronic Crohn's colitisIn this cohort of patients: A total of 663 examinations were performed on 259 patients; The median interval between examinations was 24 mo; More frequent examinations were carried out(1-6 mo) in patients with dysplasia; Dysplasia or cancer was detected in 16% (10 indefinite, 23 LGD, 4 HGD and 5 cancers); Definite dysplasia or cancer was associated with age > 45 yr and had increased symptomsColonoscopic surveillance should be strongly considered in chronic extensive Crohn's colitis. Benefit-yes. May improve survival
Biasco et al[144], 2002, Prospective Longitudinal study (20 yr duration)65 patients with UC > 7 yrIn this cohort of patients: A total of 23 (35.3%) patients had surgery; A total of 29 (44.66%) patients discontinued the programme; Only 11 (16.9%) patients have remained in the programmeResults cast some doubts on the significance of such a programme and on its long-term feasibility. Benefit-no. Long-term feasibility doubtful
Hata et al[145] 2003, Retrospective January 1979 and December 2001217 UC patientsIn this cohort of patients: A total of 15 patients were detected to have definite dysplasia; Among 5/15 proved to have invasive cancer in resected specimens; cumulative risk for development of definite dysplasia at 10, 20 and 30 yr was 3.1%, 10.0%, and 15.6% respectively; A cumulative risk for the development of invasive cancer at 10, 20, and 30 yr was 0.5%, 4.1%, and 6.1%, respectivelyThe surveillance programme is useful for detecting IBD-CRC and survival may be improved by surveillance colonoscopy. Benefit-yes. May improve survival